News | January 26, 2022
Cipla’s Q3FY22 PAT at Rs 729 cr.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
Go-ahead for pivotal clinical trial which is expected to commence by March
Biocon has reported consolidated financial results for the period ended December 31, 2021
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
This is the company’s first partnership arrangement in China
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Subscribe To Our Newsletter & Stay Updated
